<p>We interviewed two doctors, 潘志远, Pan Zhi Yuan, who specializes in research medicine and tumor treatment, and 鞠敏, Ju Min, who is a doctor of Chinese medicine. </p>
<p>After we had developed the second generation of our bacteria, we inquired him about various aspects of our project to ask for his approval before entering the actual experimentation. He carefully reviewed our project, and was in general approval of our project, although he did raise some concerns about our future implementation. He repeatedly stressed the importance of safety testing and ensuring that minimal harm is brought about to humans. Therefore, we have carefully studied the laws and regulations of China. (See the entrepreneurship page - value proposition for more details)</p>
<p>One question was about the transportation method of our bacteria into the gut. He stated that when transported from the anus, because the distance to the gut is shorter, and the bacteria do not pass through the stomach, which kills most of the bacteria, so the survival rate of the bacteria would be greater. In comparison, when we use the oral intake method, the patient's medication and treatment experience would be much better, as it is very mentally and physically uncomfortable to have the bacteria delivered via the anus. Delivering via the anus would also require the patient to come to a treatment center for delivery, reducing the accessibility of our technology. In contrast, oral can be taken anywhere without pain. However, orally delivered bacteria would lack in bacteria survival rate.</p>
<p>In recent years, hyperuricemia in China has shown a significant increase and a younger trend. Complications that hyperuricemia and ventilation are highly likely to cause include hypertension, fatty liver, chronic kidney disease, and cardiovascular diseases.</p>
